{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ivacaftor+%28VX-770%29&page=2", "query": { "intervention": "Ivacaftor (VX-770)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 110, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ivacaftor+%28VX-770%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ivacaftor+%28VX-770%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T08:24:34.578Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02347657", "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-661 Plus Ivacaftor Combination", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" }, { "name": "VX-661 Plus Ivacaftor Combination Placebo", "type": "DRUG" }, { "name": "Ivacaftor placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 510, "start_date": "2015-01", "completion_date": "2017-01-20", "has_results": true, "last_update_posted_date": "2018-06-12", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02347657" }, { "nct_id": "NCT05153317", "title": "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 71, "start_date": "2022-01-17", "completion_date": "2026-01-29", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 13, "location_summary": "Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153317" }, { "nct_id": "NCT04509050", "title": "Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor or elexacaftor/tezacaftor/ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sonya Heltshe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "10 Years", "sex": "ALL", "summary": "Up to 10 Years" }, "enrollment_count": 210, "start_date": "2020-11-18", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04509050" }, { "nct_id": "NCT01897233", "title": "Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Lumacaftor", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 62, "start_date": "2013-07", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01897233" }, { "nct_id": "NCT03150719", "title": "A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Tezacaftor/Ivacaftor", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 98, "start_date": "2017-05-24", "completion_date": "2018-08-09", "has_results": true, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150719" }, { "nct_id": "NCT03624101", "title": "Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Symdeko", "type": "DRUG" }, { "name": "Ivacaftor and Symdeko", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-12-01", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2025-04-16", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03624101" }, { "nct_id": "NCT02565914", "title": "A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1131, "start_date": "2015-08", "completion_date": "2022-12-05", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02565914" }, { "nct_id": "NCT03525574", "title": "A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 507, "start_date": "2018-10-09", "completion_date": "2023-01-09", "has_results": true, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 52, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03525574" }, { "nct_id": "NCT00457821", "title": "Safety Study of Ivacaftor in Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor 25 mg/75 mg", "type": "DRUG" }, { "name": "Ivacaftor 75 mg/150 mg", "type": "DRUG" }, { "name": "Ivacaftor 150 mg or 250 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-05", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00457821" }, { "nct_id": "NCT03224351", "title": "A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-659", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo (matched to VX-659/TEZ/IVA)", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" }, { "name": "VX-561", "type": "DRUG" }, { "name": "Placebo (matched to VX-659/TEZ/VX-561)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2017-08-08", "completion_date": "2018-02-28", "has_results": true, "last_update_posted_date": "2021-04-22", "last_synced_at": "2026-10-08T08:24:34.578Z", "location_count": 25, "location_summary": "New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Morton Grove", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03224351" } ] }